The estimated Net Worth of Daniel E. Geffken is at least $153 Mille dollars as of 29 November 2021. Mr. Geffken owns over 50,000 units of Windtree Therapeutics stock worth over $152,500 and over the last 6 years he sold WINT stock worth over $0. In addition, he makes $0 as Independent Director at Windtree Therapeutics.
Daniel has made over 2 trades of the Windtree Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of WINT stock worth $36,000 on 29 November 2021.
The largest trade he's ever made was buying 50,000 units of Windtree Therapeutics stock on 29 November 2021 worth over $36,000. On average, Daniel trades about 6,509 units every 70 days since 2019. As of 29 November 2021 he still owns at least 50,000 units of Windtree Therapeutics stock.
You can see the complete history of Mr. Geffken stock trades at the bottom of the page.
Daniel E. Geffken CPA serves as Independent Director of the Company. Mr. Geffken has been serving as the Founding Managing Partner of Danforth Advisors, a leading financial and strategy consulting firm to the life sciences industry. He has served as chief financial officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Cabaletta Bio, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Mr. Geffken has served on the Board of Elicio Bio, Alcobra Ltd. and Arcturus Inc., after its merger with Alcobra.
Daniel's mailing address filed with the SEC is C/O WINDTREE THERAPEUTICS, INC., 2600 KELLY ROAD, SUITE 100, WARRINGTON, PA, 18976.
Over the last 6 years, insiders at Windtree Therapeutics have traded over $1,982,541 worth of Windtree Therapeutics stock and bought 6,849,036 units worth $20,224,921 . The most active insiders traders include James Huang, Pharmaceutical Holdings Ltd... e Ii Investments Ltd Lph. On average, Windtree Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $425,323. The most recent stock trade was executed by Craig Fraser on 27 September 2023, trading 2,500 units of WINT stock currently worth $2,550.
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Windtree Therapeutics executives and other stock owners filed with the SEC include: